30 / 37
RECIST vs CHOI EXPERIENCE
WITH SUNITINIB IN THE PHASE III STUDY
Mean tumour density
change in target lesions
(Choi)
Changes in tumour size
(RECIST)
Median TTP according to Choi criteria
Response evaluation after 4 weeks
of sunitinib treatment
Early occurrence of response by Choi criteria at the first tumour
evaluation may better identify than RECIST patients benefiting from sunitinib
Faivre S
et al. Targ Oncol
2012